lihuang zha

Dr. lihuang zha


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
YTYiyang Tang
Yiyang Tang
XZXiaofang Zeng
Xiaofang Zeng
YFYilu Feng
Yilu Feng
QCQin Chen
Qin Chen
ZLZhenghui Liu
Zhenghui Liu
Zaixin YuZaixin Yu
Zaixin Yu
Purpose: The present study aimed to clarify the potential predictive significance of Systemic immune-inflammation index (SII) in assessing the poor prognosis of critically ill patients with congestive heart failure (CHF).Methods: Detailed clinical data were extracted from the Multiparameter Intelligent Monitoring in Intensive Care III database after gaining access and building the local platform. The 30- and 90-day and hospital all-cause mortalities of the patient was the primary outcome, and the readmission rate and the occurrence of major cardiovascular adverse events (MACEs) were the secondary outcomes. the Cox proportional hazard model and Logistic regression analysis were selected to reveal the relationship between SII level and the research outcome. Further, the propensity score matching (PSM) analysis was performed to improve the reliability of results by reducing the imbalance across groups.Results: There were a total of 4,606 subjects who passed the screening process and entered the subsequent analysis. Multivariate regression analysis showed that after adjusting for possible confounders, including age, heart rate, and albumin, etc., the high level of SII was independently associated with 30- and 90-day and hospital mortalities (tertile 3 vs. tertile 1: HR, 95% CIs: 1.23, 1.04-1.45; 1.21, 1.06-1.39; 1.26, 1.05-1.50) and the incidence of MACEs (tertile 3 vs. tertile 1: OR, 95% CI: 1.39, 1.12-1.73) in critically ill patients with CHF, but no significant correlation was found between SII and the readmission rate. Consistently, patients with high SII level still presented a significantly higher short-term mortality than patients with low SII in the PSM subset.Conclusion: In critically ill patients with CHF, high level of SII could effectively predict high 30- and 90-day and hospital mortalities, as well as the high risk of occurrence of MACEs.

24 December 2020 in Oxidative Medicine and Cellular Longevity
Verified
Journal Article
Open access
PDF file
LZlihuang zha
lihuang zha
ZYZaixin Yu
Zaixin Yu
JFJian Fang
Jian Fang
LZLi Zhou
Li Zhou
WGWen Guo
Wen Guo
JZJun Zhou
Jun Zhou
NLRC3 inhibits inflammatory responses. Neuroinflammation induces and accelerates the onset of Alzheimers disease (AD). This study is aimed at investigating whether NLRC3 plays a role in neuroinflammation, Aβ accumulation, and neuroprotection in AD mice. 12-month-old APP/PS1 transgenic and C57 mice were used for studies in vivo. In vitro, organotypic hippocampal slices were cultured. We found that the expression of NLRC3 was downregulated in the brain tissues of APP/PS1 mice. Mice in the APP/PS1 group had a significant attenuation of learning and memory ability compared to the control group, and the ability was improved in APP/PS1+LV-NLRC3 mice. The expressions of 6E10, GFAP, Iba1, and PI3K in the hippocampus and brains of APP/PS1 mice were significantly higher than those of the control group, while the expressions of NeuN were lower than that of the control group. With the overexpression of NLRC3 in the APP/PS1+LV-NLRC3 group, the expressions of 6e10, GFAP, Iba1, and PI3K were significantly lower, while the expression of NeuN was significantly higher compared to the APP/PS1 group. NLRC3 colocalized with NeuN. PI3K activation with 740YP increased the expression of GFAP and Iba-1 in the hippocampus with the exogenous NLRC3 protein. We conclude that NLRC3 may play an important role in the development and progression of AD. Downregulation of NLRC3 can lead to the activation of PI3K, resulting in abnormal plaque deposition, glial cell activation, and neuron loss during AD. NLRC3 delays the progression of AD in APP/PS1 mice via inhibiting PI3K activation.

13 May 2024 in Aging Cell
Verified
Journal Article
Open access
YTYiyang Tang
Yiyang Tang
ZLZhenghui Liu
Zhenghui Liu
QCQin Chen
Qin Chen
MJMukamengjiang Juaiti
Mukamengjiang Juaiti
ZYZaixin Yu
Zaixin Yu
LZlihuang zha
lihuang zha
The relationship between sarcopenia and the long‐term risk of atrial fibrillation (AF) remains unclear. This study recruited a large prospective Caucasian cohort from the UK Biobank. Participants were assessed at baseline with handgrip strength and muscle mass and were categorized into groups of non‐sarcopenia, probable sarcopenia, and confirmed sarcopenia. Kaplan–Meier method and Cox proportional hazards model were used to explore the association between sarcopenia and the incidence of AF. The genetic predisposition of AF was assessed by polygenic risk score. Sensitivity analyses were performed to validate the results. A total of 384,433 participants with a median age of 58 years and 54.3% women were enrolled in this study. There were 24,007 cases of new‐onset AF over a median follow‐up of 12.56 years. The groups of non‐sarcopenia, probable sarcopenia, and confirmed sarcopenia accounted for 22,290 (6.1%), 1665 (9.2%), and 52 (11.9%) cases, respectively. Compared with the non‐sarcopenia group, participants with probable sarcopenia or confirmed sarcopenia had an 8% (95% CI, 1.03–1.14) or 61% (95% CI, 1.23–2.12) higher risk of AF incidence. The findings remained robust in multiple sensitivity analyses, such as subgroup analysis and further adjustment of genetic predisposition. Notably, the association between sarcopenia and a high AF risk was more pronounced in younger participants, women, and those with valvular heart disease. In conclusion, sarcopenia was associated with a high long‐term risk of AF in Caucasians, supporting sarcopenia as a new independent risk factor of AF.

14 February 2019 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LZlihuang zha
lihuang zha
JZJun Zhou
Jun Zhou
TLTang‐Zhiming Li
Tang‐Zhiming Li
HLHui Luo
Hui Luo
MZMen‐Qiu Zhang
Men‐Qiu Zhang
Zaixin YuZaixin Yu
Zaixin Yu

25 September 2024 in iScience
Verified
Journal Article
Open access
BLBenhui Liang
Benhui Liang
WLWenchao Lin
Wenchao Lin
YTYiyang Tang
Yiyang Tang
TLTangzhiming Li
Tangzhiming Li
QCQin Chen
Qin Chen
MZMengqiu Zhang
Mengqiu Zhang
Pulmonary arterial hypertension (PAH) is a life-threatening disease induced by abnormal activation of pulmonary adventitial fibroblasts (PAFs) in the early stage. The association between selenium deficiency and PAH is not yet fully understood. In this study, we found that the serum selenium content of PAH patients was significantly lower than that of healthy volunteers in two independent cohorts. Moreover, PAH patients with lower selenium levels may present poorer prognosis. Prophylactic selenium supplementation could effectively improve hemodynamics and pulmonary vascular remodeling in monocrotaline-induced pulmonary hypertension rat models. Mechanistically, selenium supplementation restored the level of selenium binding protein 1 (SELENBP1) which could exert an antagonistic effect on PAF activation. The rescue assay further proved that selenium supplementation worked in a SELENBP1-dependent manner. These findings demonstrated that selenium deficiency is an important risk factor in PAH, and the selenium-SELENBP1 axis represents a promising target for PAH prevention.

7 May 2020 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
LZlihuang zha
lihuang zha
JZJun Zhou
Jun Zhou
YTYilong Tan
Yilong Tan
SGShuhong Guo
Shuhong Guo
MZMen‐Qiu Zhang
Men‐Qiu Zhang
Zaixin YuZaixin Yu
Zaixin Yu